INVA
INVA
NASDAQ · Pharmaceuticals

Innoviva Inc

$19.24
-2.02 (-9.50%)
As of Nov 7, 1:48 AM ET ·
Financial Highlights (FY 2026)
Revenue
354.52M
Net Income
233.71M
Gross Margin
74.8%
Profit Margin
65.9%
Rev Growth
+7.5%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 354.52M 329.85M 296.49M 325.02M
Gross Profit 265.18M 246.72M 199.68M 218.90M
Operating Income 141.13M 118.18M 108.77M 141.90M
Net Income 233.71M 195.70M 100.45M 107.69M
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Rev Growth +7.5% +7.5% +12.4% +2.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 126.59M 126.59M 569.66M 644.56M
Total Equity 576.18M 576.18M 1.17B 1.19B
D/E Ratio 0.22 0.22 0.49 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 153.16M 135.37M 161.71M 177.91M
Free Cash Flow — — 84.32M 106.96M